Rentschler Biopharma

Discover more about the expertise driving reliability you can trust at our state-of-the-art manufacturing site in Milford, MA and meet the passionate team behind our success. Today we start with Tom Roberts, President and General Manager Rentschler Biopharma Inc.     “We are a leading global CDMO that has been around for 150+ years. Here at our Milford, MA site, we offer integrated solutions from process development to cGMP manufacturing of biopharmaceuticals. As a company, we are committed to advancing medicine to save lives.     At our Milford facility, we have grown from a single-product commercial facility to a multi-product facility. This is an exciting time for us, as this is the most significant expansion in the company's history and will double our global cGMP capacity. As industry legislation evolves, we remain committed to responsibly supporting our clients and contributing positively to both national interests and global health advancements.    We don’t just manufacture medicines here; we're truly shaping the future of healthcare and making a difference in the lives of patients worldwide.”    #RentschlerBiopharma #CDMO #ReliabilityYouCanTrust 

We are pleased to announce that our new, state-of-the-art production line in Milford, MA, is now fully operational! This expansion is the largest in our history and doubles our global capacity to meet the growing demand for biopharmaceuticals that support patients with rare and serious diseases. The first major client project is already underway, and we continue to welcome new projects and clients. Interested? Then get in touch and find out how we can support you. https://lnkd.in/ecYrZ-Md Benedikt von Braunmühl, CEO of Rentschler Biopharma SE, commented: “As a fifth-generation, family-owned company, we stand at the forefront of manufacturing innovative therapies for patients with serious and rare diseases worldwide. The completion of our new, state-of-the-art production line is an important milestone for our company and emphasizes Rentschler Biopharma’s strong capabilities in the U.S. Our clients are our partners, and we are working with them to empower tomorrow’s therapies today. Indeed, in 2023, Rentschler Biopharma was proud to contribute to nearly 25% of the biopharmaceuticals approved by the U.S. FDA. I would like to thank our teams on both sides of the Atlantic who worked tirelessly together to get this important facility online.” Tom Roberts, President of Rentschler Biopharma Inc. and General Manager U.S. noted: “Our new line is vital to growing our business and effectively serving the U.S. market, and I am excited about bringing in new clients as well as expanding our support of existing ones with a reliability they can trust. I also would like to extend my gratitude to the entire team for their strong support in getting this important new production line up and running. We are embarking on a new stage in our long and successful history and are poised to tackle the most complex challenges in biopharmaceutical development and manufacturing. In light of evolving industry legislation, we remain committed to supporting our clients responsibly and contributing positively to both national interests and global health advancements.”   #RentschlerBiopharma #CDMO #ReliabilityYouCanTrust https://lnkd.in/gjEFWqXA

July marks four years of our strategic collaboration with Vetter Pharma. Four years in which we have been teaming up with the joint goal to simplify processes and optimize time-to-market for our clients. Today, our strategic collaboration Xpert Alliance synergizes the expertise of both of our companies along the entire value chain of the project lifecycle (Drug Substance to Drug Product). Together, we find the most suitable full-service solutions to maximize product potential while meeting the clinical and commercial needs of our clients. Find out more about our Xpert Alliance here: https://lnkd.in/e-rpwy84  

As a family-owned company with more than 150 years of history, responsibility is one of our core values. We are pleased to announce that we have joined the UN Global Compact, the world’s largest corporate sustainability initiative.     This commitment to responsible business practices aligns with our core values and demonstrates our dedication to upholding the ten principles of the UN Global Compact which cover human and labor rights, environmental protection, and business conduct. Our annual progress report, which will provide a transparent and comprehensive account of our sustainability activities, will support our ambition to create value sustainably. For more information about sustainability at Rentschler Biopharma, please visit our website: https://lnkd.in/e5ifngBu    #RentschlerBiopharma #CDMO #GlobalCompact 

Happy Independence Day from all of us at Rentschler Biopharma! To our valued clients and partners, thank you for your ongoing collaboration and support. Together, we are committed to advancing medicine to save lives. #RentschlerBiopharma #CDMO

In today’s world, data is the key. But how do companies ensure that the data they collect is accurate and valuable to their business? Thomas aus dem Siepen, our Global Head Digital Manufacturing and Automation, recently met with smart industry experts at the Manufacturing & Smart Industry Summit DACH to discuss how to generate data with context and thus valuable information. Here are his 5 insights on overcoming the challenges of big data in the CDMO industry.    Musin Mawlood #RentschlerBiopharma #CDMO #DataIntegrity

Last week, Christiane Bardroff, our COO, attended the “TREFFpunkt Gesundheitsindustrie 2024”, a networking event for the healthcare industry in Baden-Wuerttemberg. During the panel discussion "Innovations in medicine - for everyone?", Christiane joined industry experts in exploring different ideas on how innovations can improve healthcare and keep medicine affordable for everyone.      Christiane shared her vision for the medicine of the future in the year 2035: “My goal is to strive for affordable, stratified healthcare, that helps everyone maintain and improve their health. In my opinion, a collaborative team approach is key to realizing this vision. It is necessary that all stakeholders have a common focus and that patients, government, authorities, pharmaceutical companies and CDMOs work together efficiently and reduce bureaucracy. We did a fantastic job during the Covid-19 pandemic, where we produced more than 2 bn doses of the vaccine in short time, which enabled rapid progress and helped save many lives. This goes hand in hand with our corporate vision, which we pursue every day at Rentschler Biopharma: Advancing medicine to save lives. Together.”    Copyright: BIOPRO Baden-Württemberg GmbH    #RentschlerBiopharma #CDMO #BPCluster 

At our licensed, multi-product manufacturing site in Milford, MA, USA, we are dedicated to full-service solutions along the biopharmaceutical value chain. Under the leadership of Tom Roberts and a commitment to excellence, we offer reliability you can trust.  Our state-of-the-art facility and highly experienced team are poised to tackle the most complex challenges in bioprocess development and cGMP manufacturing. To meet growing demand and enhance our capabilities, we've expanded our capacities at Milford. Be the first to view our new and active state-of-the-art manufacturing suite, which houses four 2,000-liter single-use bioreactors and added manufacturing cleanroom space.  Join us as we continue to innovate, expand, and make a difference in the lives of patients by advancing medicine to save lives, worldwide. #RentschlerBiopharma #CDMO #ReliabilityYouCanTrust

We are thrilled to announce that we will be attending the British Society for Gene and Cell Therapy (BSGCT) conference in Oxford from June 17-19. Our ATMP team, including Saerah Khan and Bertille Boudier, looks forward to engaging with experts from the industry and academic community, sharing insights, and exploring latest advancements in the gene therapy space.     Learn more about our advanced therapy capabilities here: https://lnkd.in/eHuE5B9j    #BSGCT #genetherapy #advancedtherapies #ATMP #rentschlerbiopharma #conference 

Are you attending the Gene Therapy Development conference in London this week? Do not miss the opportunity to hear from Peter Archibald, our Process Development Manager on Thursday, June 13 at 12:10 pm BST. In his talk, ‘Optimizing AAV full capsids and the importance of early DSP (downstream processing) assessment in upstream processing’, Peter will discuss the key upstream processing (USP) transfection parameters, the use of DoE (design of experiments) to optimize VP and VG titres, the development of a small-scale downstream process to augment USP development and the methods available for accurate determination of the full/empty ratio.    Make sure to visit us at stand #1 where you’ll have the chance to meet our gene therapy experts, including Robert Panting, Saerah Khan and Bertille Boudier and discuss your upcoming advanced therapy programs.    Follow the link to learn more about the event and schedule a meeting with our team: https://lnkd.in/du7kSpDv #RentschlerBiopharma #AdvancedTherapies #genetherapy #processdevelopment #AAV #OGCell #GeneTherapy24